---
title: "Vireo Growth (VREOF) stock: news and investor profile"
url: "https://aibio.space/companies/vireo-growth/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "Vireo Growth Inc. (OTC: VREOF), United States. Listing facts, related biotech companies and news on aibio.space."
---

VREOF Vireo Growth Inc. OTC · United States

# Vireo Growth (VREOF) news

Vireo Growth Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker VREOF, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

## Latest Vireo Growth news

We have not published a story on Vireo Growth yet. When there is news, it will appear here.

## Vireo Growth at a glance

- **Ticker**: VREOF

- **Listing**: OTC

- **Country**: United States

- **Cash, Jun 30, 2026**: $123.7 million

### Related companies

- [METTLER TOLEDO INTERNATIONAL INC/](https://aibio.space/companies/mettler-toledo-international/) NYSE: MTD
- [HARVARD BIOSCIENCE INC](https://aibio.space/companies/harvard-bioscience/) NASDAQ: HBIO
- [Fresenius SE & Co. KGaA](https://aibio.space/companies/fresenius-fsnuy/) OTC: FSNUY
- [COOPER COMPANIES, INC.](https://aibio.space/companies/cooper-companies/) NASDAQ: COO
- [TACTILE SYSTEMS TECHNOLOGY INC](https://aibio.space/companies/tactile-systems-technology/) NASDAQ: TCMD
- [ILLUMINA, INC.](https://aibio.space/companies/illumina/) NASDAQ: ILMN
- [C21 Investments](https://aibio.space/companies/c21-investments/) OTC: CWLXF
- [Leef Brands](https://aibio.space/companies/leef-brands/) OTC: LEEEF

### Also on OTC

- [Aoxing Pharmaceutical Company](https://aibio.space/companies/aoxing-pharmaceutical/) AOXG
- [Lipella Pharmaceuticals](https://aibio.space/companies/lipella-pharmaceuticals/) LIPO
- [Zomedica](https://aibio.space/companies/zomedica/) ZOMDF
- [Avenue Therapeutics](https://aibio.space/companies/avenue-therapeutics/) ATXI
- [Calithera Biosciences](https://aibio.space/companies/calithera-biosciences/) CALA
- [Renalytix](https://aibio.space/companies/renalytix/) RNLXY

## Vireo Growth annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$268.8 million](https://www.sec.gov/Archives/edgar/data/1771706/000110465926029561/) | [$99.4 million](https://www.sec.gov/Archives/edgar/data/1771706/000110465926029561/) |
| Net income (loss) | [-$68.1 million](https://www.sec.gov/Archives/edgar/data/1771706/000110465926029561/) | [-$28.0 million](https://www.sec.gov/Archives/edgar/data/1771706/000110465926029561/) |
| Cash from operations | [$3.7 million](https://www.sec.gov/Archives/edgar/data/1771706/000110465926029561/) | [-$10.2 million](https://www.sec.gov/Archives/edgar/data/1771706/000110465926029561/) |
| Cash and equivalents | [$122.5 million](https://www.sec.gov/Archives/edgar/data/1771706/000110465926097118/) | [$91.6 million](https://www.sec.gov/Archives/edgar/data/1771706/000110465926097118/) |
| Short-term investments | [$1.0 million](https://www.sec.gov/Archives/edgar/data/1771706/000110465926097118/) |  |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $122.7 million, plus short-term investments of $1.0 million, $123.7 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Vireo Growth

What is the ticker symbol of Vireo Growth?

Vireo Growth Inc. trades under the ticker VREOF on OTC.

Where is Vireo Growth listed?

Vireo Growth Inc. is listed on OTC.

Which country or territory is Vireo Growth listed under?

Our directory records Vireo Growth Inc. under United States.

Does aibio.space cover Vireo Growth?

aibio.space lists Vireo Growth Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

What was Vireo Growth's revenue last year?

$268.8 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Vireo Growth profitable?

Vireo Growth Inc. reported a net loss of $68.1 million for the fiscal year ended Dec 31, 2025, and generated $3.7 million of cash from operations, per its annual report to the SEC.

How much cash does Vireo Growth have?

$123.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.

## Investor discussion: Vireo Growth

Members talk about Vireo Growth (VREOF). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Vireo Growth, newest first. Each line links the filing it comes from.

1. 2026-08-26 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1771706/000110465926101481/tm2623956d2_ex99-1.htm)
2. 2026-08-18 Financings Announced a share repurchase program. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1771706/000110465926098337/tm2623495d1_ex99-1.htm)
3. 2026-07-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1771706/000110465926086874/tm2621363d1_ex99-1.htm)
4. 2026-07-27 Mergers Reported a merger or acquisition agreement. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1771706/000110465926086877/tm2621363d1_8k.htm)
5. 2026-07-23 Distress Reported a bankruptcy filing. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1771706/000110465926086256/tm2621146d1_ex99-1.htm)
6. 2026-06-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1771706/000110465926075721/tm2617497d3_ex99-1.htm)
7. 2026-06-11 Listings Reported a reverse stock split. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1771706/000110465926072935/tm2617497d1_ex99-1.htm)
8. 2026-06-09 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1771706/000110465926071886/tm2617168d1_ex99-1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:VREOF on TradingView](https://www.tradingview.com/symbols/OTC-VREOF/).

## Listing details

Vireo Growth Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker VREOF, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Vireo Growth Inc.

- **Ticker**: VREOF

- **Listing**: OTC

- **Country or territory**: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/vireo-growth/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Vireo Growth (VREOF) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/vireo-growth/